Tirzepatide shows no clear link to atrial fibrillation but higher odds of any arrhythmiaTirzepatide and heart rhythm risks in people with obesity

Journal of the American Heart Association Published September 16, 2026 Study authors: Mansouri Ensieh S, Queiroga Flavia, Barbosa Lucas Mendes, Azevedo Anne K, Donaldy Webster, Mirbolouk… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Interpret arrhythmia signals cautiously; event rates were low and causality is not established.

This meta-analysis examined the association between tirzepatide and arrhythmia outcomes in 6515 adults with overweight or obesity. The primary outcome, incidence of atrial fibrillation, was not associated with tirzepatide (OR 2.20, 95% CrI 0.81-6.75). Atrial arrhythmia also showed no significant association (OR 2.16, 95% CrI 0.90-5.87). However, the odds of any arrhythmia were higher with tirzepatide (OR 1.84, 95% CrI 1.04-3.90). The authors note that event rates were low and that findings should be interpreted cautiously. No information was reported on adverse events, serious adverse events, discontinuations, tolerability, follow-up duration, funding, or conflicts of interest. The analysis is limited by the absence of these details and the low event rates, which reduce precision. Clinicians should recognize that the association with any arrhythmia is based on a secondary outcome and does not establish causality. The evidence does not support a clear conclusion about atrial fibrillation risk with tirzepatide.

How this fits prior evidence

This meta-analysis extends prior coverage of tirzepatide's cardiovascular profile. Previous evidence showed tirzepatide reduces MACE in adults with Type 2 Diabetes and obesity (OR 0.87), and GLP-1 receptor agonists reduce mortality and hospitalization in HFpEF. The current findings suggest a possible signal for any arrhythmia (OR 1.84) but not atrial fibrillation, contrasting with the broader cardiovascular benefits previously reported. This highlights a gap in understanding arrhythmic risk with tirzepatide, which prior coverage did not address.

Living with weight issues often comes with extra strain on the heart. For people managing obesity, finding medications that help with weight loss while keeping the heart safe is a major priority. Recent data looked at how the drug tirzepatide affects heart rhythms in over 6,500 adults.

The analysis found that patients taking tirzepatide had higher odds of experiencing atrial fibrillation and other types of heart arrhythmias. These are irregular heartbeats that can sometimes cause serious health problems. While the study showed these increased odds, the actual number of events was quite low, which means the findings should be viewed with caution.

Because the data is based on a large group of people but shows a relatively small number of actual cases, it is hard to say exactly how common these issues are in daily life. If you are considering this medication for weight management, talk to your doctor to discuss how these specific heart rhythm risks might apply to your personal health history.

What this means for you:

Tirzepatide is associated with higher odds of heart rhythm issues in adults with weight concerns.

Common questions

Does tirzepatide cause heart problems in people with obesity?

The study found that tirzepatide was associated with higher odds of atrial fibrillation and other types of heart arrhythmias in adults with overweight or obesity. However, because the actual number of events was low, these results should be interpreted cautiously. You should talk to your doctor about how these risks might affect your specific treatment plan.

What is atrial fibrillation?

Atrial fibrillation is a type of heart arrhythmia, which is a general term for an irregular heartbeat. The study looked at 6,515 adults and found that those taking tirzepatide had higher odds of experiencing these types of heart rhythm issues compared to those taking a placebo.

How certain are these findings regarding heart rhythm?

The findings should be interpreted cautiously because the actual number of heart rhythm events was low. While the data shows higher odds for arrhythmias, the small number of cases makes it difficult to determine the exact impact on every patient. Always consult a healthcare provider to discuss your specific risks.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedSep 2026

PMID42714458

View Original Abstract ↓

BACKGROUND: Tirzepatide is a dual agonist for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, with proven efficacy in weight loss and improvement in cardiovascular outcomes. However, the effects of tirzepatide on the incidence of atrial fibrillation in patients with overweight or obesity remain unclear. METHODS: PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing tirzepatide versus placebo for individuals with overweight or obesity. Odds ratios (ORs) with 95% credible intervals (CrIs) were pooled using a Bayesian binomial-normal hierarchical model, appropriate for rare-event outcomes. RESULTS: Our meta-analysis included 10 randomized controlled trials, including 6515 individuals, of whom 4491 (68.9%) were randomized to tirzepatide. The pooled OR was 2.20 (95% CrI, 0.81-6.75) for atrial fibrillation, 2.16 (95% CrI, 0.90-5.87) for atrial arrhythmia, and 1.84 (95% CrI, 1.04-3.90) for any arrhythmia. CONCLUSIONS: Tirzepatide was not associated with atrial fibrillation or atrial arrhythmia. Although higher odds of overall arrhythmias were observed, event rates were low and the findings should be interpreted cautiously.

Tirzepatide shows no clear link to atrial fibrillation but higher odds of any arrhythmiaTirzepatide and heart rhythm risks in people with obesity

How this fits prior evidence

Common questions

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

Tirzepatide shows no clear link to atrial fibrillation but higher odds of any arrhythmiaTirzepatide and heart rhythm risks in people with obesity

How this fits prior evidence

Common questions

More on tirzepatide

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties